Inflammation and cancer stem cells

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 271-278

  Shigdar, Sarah ^a   Li, Yong ^b   Bhattacharya, Santanu ^c   O'Connor, Michael ^a   Pu, Chunwen ^d   Lin, Jia ^a   Wang, Tao ^a   Xiang, Dongxi ^a   Kong, Lingxue ^e   Wei, Ming Q ^a   Zhu, Yimin ^f   Zhou, Shufeng ^g   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c INDIAN INSTITUTE OF SCIENCE   (India)

^d Dalian Sixth People's Hospital   (China)

^e GRIFFITH UNIVERSITY   (Australia)

^f SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer stem cells; Epigenetics; Epithelial mesenchymal transition; Inflammation; Microenvironment

Indexed keywords

BETA CATENIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PROTEIN P53; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL MIGRATION; CYTOKINE RELEASE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SHORT SURVEY;

CANCER STEM CELLS; EPIGENETICS; EPITHELIAL-MESENCHYMAL TRANSITION; INFLAMMATION; MICROENVIRONMENT;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84896709234     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.031     Document Type: Review

References (100)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: Cancer J. Clinic. 2012, 62:10-29.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
3. Koch U., Krause M., Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective. Semin. Cancer Biol. 2010, 20:116-124.
4. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 2010, 20:85-92.
5. Ebben J.D., Treisman D.M., Zorniak M., Kutty R.G., Clark P.A., Kuo J.S. The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin. Ther. Targets 2010, 14:621-632.
6. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
7. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
8. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
9. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
10. Kvinlaug B.T., Huntly B.J. Targeting cancer stem cells. Expert Opin. Ther. Targets 2007, 11:915-927.
11. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
12. O'Brien C.A., Kreso A., Jamieson C.H.M. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16:3113-3120.
13. Trumpp A., Wiestler O.D. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 2008, 5:337-347.
14. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 2011, 89:491-502.
15. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
16. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
17. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
18. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4:221-233.
19. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
20. Jarnicki A., Putoczki T., Ernst M. Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?. Cell Div. 2010, 5:14.
21. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. 2009, 9:265-273.
22. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin. Cancer Biol. 2012.
23. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108:7950-7955.
24. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
25. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 2012, 22:699-701.
26. Bjornson C.R.R., Rietze R.L., Reynolds B.A., Magli M.C., Vescovi A.L. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999, 283:534-537.
27. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
28. Petersen B.E., Bowen W.C., Patrene K.D., Mars W.M., Sullivan A.K., Murase N., Boggs S.S., Greenberger J.S., Goff J.P. Bone marrow as a potential source of hepatic oval cells. Science 1999, 284:1168-1170.
29. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
30. Smit M.A., Peeper D.S. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging 2010, 2:735-741.
31. Rajabi H., Alam M., Takahashi H., Kharbanda A., Guha M., Ahmad R., Kufe D. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2013.
32. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. 2007, 7:415-428.
33. West N.R., Murray J.I., Watson P.H. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2013.
34. Min C., Eddy S.F., Sherr D.H., Sonenshein G.E. NF-kappaB and epithelial to mesenchymal transition of cancer. J. Cell Biochem. 2008, 104:733-744.
35. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
36. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
37. Shigdar S., Lin J., Li Y., Yang C.J., Wei M., Zhus Y., Liu H., Duan W. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Ther. Deliv. 2012, 3:227-244.
38. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98:1512-1520.
39. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., Quraishi A.A., Tawakkol N., D'Angelo R., Paulson A.K., Chung S., Luther T., Paholak H.J., Liu S., Hassan K.A., Zen Q., Clouthier S.G., Wicha M.S. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584.
40. Hirsch H.A., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. USA 2013, 110:972-977.
41. Liu M., Sakamaki T., Casimiro M.C., Willmarth N.E., Quong A.A., Ju X., Ojeifo J., Jiao X., Yeow W.S., Katiyar S., Shirley L.A., Joyce D., Lisanti M.P., Albanese C., Pestell R.G. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 2010, 70:10464-10473.
42. Katoh M., Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 2007, 13:4042-4045.
43. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Develop. Cell 2008, 14:818-829.
44. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
45. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
46. Moore N., Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J. Oncol. 2011.
47. Karamboulas C., Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 1830, 2013:2481-2495.
48. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15:338-344.
49. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. 2009, 9:400-414.
50. Ninov N., Borius M., Stainier D.Y. Different levels of Notch signaling regulate quiescence, renewal and differentiation in pancreatic endocrine progenitors. Development 2012, 139:1557-1567.
51. Hassan K.A., Wang L., Korkaya H., Chen G., Maillard I., Beer D.G., Kalemkerian G.P., Wicha M.S. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 2013.
52. Qiu M., Peng Q., Jiang I., Carroll C., Han G., Rymer I., Lippincott J., Zachwieja J., Gajiwala K., Kraynov E., Thibault S., Stone D., Gao Y., Sofia S., Gallo J., Li G., Yang J., Li K., Wei P. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett. 2013, 328:261-270.
53. Stone D.M., Hynes M., Armanini M., Swanson T.A., Gu Q., Johnson R.L., Scott M.P., Pennica D., Goddard A., Phillips H., Noll M., Hooper J.E., de Sauvage F., Rosenthal A. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996, 384:129-134.
54. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9:873-886.
55. Song Z., Yue W., Wei B., Wang N., Li T., Guan L., Shi S., Zeng Q., Pei X., Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 2011, 6:e17687.
56. Abe Y., Oda-Sato E., Tobiume K., Kawauchi K., Taya Y., Okamoto K., Oren M., Tanaka N. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc. Natl. Acad. Sci. USA 2008, 105:4838-4843.
57. Nakashima H., Nakamura M., Yamaguchi H., Yamanaka N., Akiyoshi T., Koga K., Yamaguchi K., Tsuneyoshi M., Tanaka M., Katano M. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 2006, 66:7041-7049.
58. Su Y.C., Li S.C., Wu Y.C., Wang L.M., Chao K.S., Liao H.F. Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia. Evidence-Based Complement. Altern. Med.: eCAM 2013, 2013:547430.
59. Li S.H., Fu J., Watkins D.N., Srivastava R.K., Shankar S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol. Cell Biochem. 2013, 373:217-227.
60. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K.L., Matsui W., Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67:2187-2196.
61. Kasperczyk H., Baumann B., Debatin K.M., Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 2009, 23:21-33.
62. Cui W., Wang L.H., Wen Y.Y., Song M., Li B.L., Chen X.L., Xu M., An S.X., Zhao J., Lu Y.Y., Mi X.Y., Wang E.H. Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci. 2010, 101:927-933.
63. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
64. Yan H.X., Wu H.P., Zhang H.L., Ashton C., Tong C., Wu J., Qian Q.J., Wang H.Y., Ying Q.L. DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats. Oncogene 2012.
65. Berns A. Cancer: the blind spot of p53. Nature 2010, 468:519-520.
66. Schwitalla S., Ziegler P.K., Horst D., Becker V., Kerle I., Begus-Nahrmann Y., Lechel A., Rudolph K.L., Langer R., Slotta-Huspenina J., Bader F.G., Prazeres da Costa O., Neurath M.F., Meining A., Kirchner T., Greten F.R. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013, 23:93-106.
67. Yan H.X., Wu H.P., Zhang H.L., Ashton C., Tong C., Wu H., Qian Q.J., Wang H.Y., Ying Q.L. p53 Promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J. Hepatol. 2013.
68. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993, 74:813-822.
69. Son D.S., Kabir S.M., Dong Y.L., Lee E., Adunyah S.E. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IkappaB. PLoS One 2012, 7:e51116.
70. Cooks T., Pateras I.S., Tarcic O., Solomon H., Schetter A.J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rozenfeld N., Harpaz N., Itzkowitz S., Harris C.C., Rotter V., Gorgoulis V.G., Oren M. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
71. Tanno T., Matsui W. Development and maintenance of cancer stem cells under chronic inflammation. J. Nippon Med. Sch. 2011, 78:138-145.
72. Bierie B., Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Fact. Rev. 2010, 21:49-59.
73. Hollier B.G., Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia. 2009, 14:29-43.
74. Biswas S.K., Allavena P., Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013.
75. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 2013, 138:657-664.
76. Kim S.Y., Kang J.W., Song X., Kim B.K., Yoo Y.D., Kwon Y.T., Lee Y.J. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal. 2013, 25:961-969.
77. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
78. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., Jung Y., Dontu G., Taichman R., Wicha M.S. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71:614-624.
79. Vermeulen L., De Sousa E Melo F., Van Der Heijden M., Cameron K., De Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
80. Levina V., Marrangoni A.M., DeMarco R., Gorelik E., Lokshin A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3:e3077.
81. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 2011, 121:3804-3809.
82. Ji Y., Zhang W. Th17 cells: positive or negative role in tumor?. Cancer Immunol. Immunother. 2010, 59:979-987.
83. Stewart D.A., Yang Y., Makowski L., Troester M.A. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol. Cancer Res. 2012, 10:727-738.
84. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
85. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
86. Bao B., Ahmad A., Kong D., Ali S., Azmi A.S., Li Y., Banerjee S., Padhye S., Sarkar F.H. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 2012, 7:e43726.
87. Baylin S.B. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc. Am. Thoracic Soc. 2012, 9:64-65.
88. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
89. D'Anello L., Sansone P., Storci G., Mitrugno V., D'Uva G., Chieco P., Bonafe M. Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol. Cancer 2010, 9:300.
90. Hodge D.R., Peng B., Cherry J.C., Hurt E.M., Fox S.D., Kelley J.A., Munroe D.J., Farrar W.L. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005, 65:4673-4682.
91. van Vlerken L.E., Kiefer C.M., Morehouse C., Li Y., Groves C., Wilson S.D., Yao Y., Hollingsworth R.E., Hurt E.M. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Translat. Med. 2013, 2:43-52.
92. Wheeler D.L., Iida M., Dunn E.F. The role of Src in solid tumors. Oncologist 2009, 14:667-678.
93. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
94. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
95. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., Thompson J.C., Caserta E., Wang H., Chong J.L., Naidu S., Wei G., Sharma S.M., Stephens J.A., Fernandez S.A., Gurcan M.N., Weinstein M.B., Barsky S.H., Yee L., Rosol T.J., Stromberg P.C., Robinson M.L., Pepin F., Hallett M., Park M., Ostrowski M.C., Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
96. Tanwar P.S., Zhang L., Roberts D.J., Teixeira J.M. Stromal deletion of the APC tumor suppressor in mice triggers development of endometrial cancer. Cancer Res. 2011, 71:1584-1596.
97. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., Platzer P., Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 2007, 357:2543-2551.
98. Achyut B.R., Bader D.A., Robles A.I., Wangsa D., Harris C.C., Ried T., Yang L. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet. 2013, 9:e1003251.
99. Blanpain C. Tracing the cellular origin of cancer. Nat. Cell. Biol. 2013, 15:126-134.
100. Wang R.A., Li Z.S., Zhang H.Z., Zheng P.J., Li Q.L., Shi J.G., Yan Q.G., Ye J., Wang J.B., Guo Y., Huang X.F., Yu Y.H. Invasive cancers are not necessarily from preformed in situ tumours-an alternative way of carcinogenesis from misplaced stem cells. J. Cell. Mol. Med. 2013.